A study published on November 6, 2025, in Oncotarget(Volume 16) reveals that LRIG1 protein expression significantly decreases in higher-grade gliomas, suggesting its potential as both a biomarker for tumor aggressiveness and a therapeutic target.
Conducted by researchers at the University of Cologne, the investigation analyzed LRIG protein family expression patterns across glioma grades, providing new insights into the molecular mechanisms driving brain tumor progression and patient outcomes.
Study Design and Methodology
The research team examined patient-derived glioma samples to quantify expression levels of three related proteins—LRIG1, LRIG2, and LRIG3—across different tumor grades.
These proteins regulate cellular growth signaling pathways, with previous studies indicating tumor-suppressive roles for LRIG1 and LRIG3, while LRIG2 may promote tumor growth. The study correlated protein expression patterns with tumor classification, treatment response, and clinical outcomes.
Key Findings on LRIG1 Expression
Analysis revealed a strong inverse relationship between LRIG1 levels and glioma malignancy:
Grade-dependent decrease: LRIG1 protein expression declined significantly as tumor grade increased
Low-grade gliomas: Showed substantially higher LRIG1 expression compared to high-grade tumors
Glioblastoma subtypes: Primary glioblastomas exhibited the lowest LRIG1 levels, while secondary glioblastomas (developing from lower-grade tumors) maintained higher expression, potentially explaining their relatively better clinical outcomes
Complex Patterns in LRIG2 and LRIG3
The study uncovered nuanced expression patterns for other LRIG family members:
LRIG2: Demonstrated a disconnect between gene expression (higher in low-grade tumors) and protein levels (slightly elevated in high-grade tumors), suggesting post-transcriptional regulation
LRIG3: Showed higher expression in glioma tissue compared to healthy brain tissue, particularly in low-grade tumors, with inconsistent response to chemotherapy across tumor types
Clinical Implications and Future Directions
“These findings position LRIG1 as a promising biomarker for glioma stratification and a potential therapeutic target,” stated the research team. The inverse correlation between LRIG1 expression and tumor grade suggests its role in suppressing glioma progression.
While chemotherapy did not consistently alter LRIG protein expression, their diagnostic and therapeutic potential warrants further investigation into the underlying mechanisms driving these expression patterns and their functional consequences in glioma pathogenesis.
Research Context and Patient Impact
As the most common malignant brain tumors in adults, gliomas—particularly glioblastomas—carry poor prognoses. This research contributes to the growing understanding of molecular drivers behind tumor aggressiveness
potentially enabling improved diagnosis, prognosis prediction, and development of targeted therapies for glioma patients. Future studies will focus on validating these findings in larger cohorts and exploring therapeutic strategies to modulate LRIG protein activity.
Related topics
